Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ZW191 |
| Synonyms | |
| Therapy Description |
ZW191 is an antibody-drug conjugate (ADC) comprising an antibody targeting FOLR1 (FRalpha) conjugated to a topoisomerase I inhibitor payload, ZD06519, which potentially induces antitumor activity (Cancer Res (2024) 84 (6_Supplement): 1862). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ZW191 | ZW-191|ZW 191 | FOLR1-targeted Therapy 24 | ZW191 is an antibody-drug conjugate (ADC) comprising an antibody targeting FOLR1 (FRalpha) conjugated to a topoisomerase I inhibitor payload, ZD06519, which potentially induces antitumor activity (Cancer Res (2024) 84 (6_Supplement): 1862). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06555744 | Phase I | ZW191 | A Study of ZW191 in Participants With Solid Tumors | Recruiting | USA | AUS | 3 |